0001562762-21-000494 | 10-Q | XBRL Viewer

Print Document View Excel Document

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2021	Dec. 17, 2021
Document And Entity Information [Abstract]
Entity Registrant Name	Vaxxinity, Inc.
Entity Central Index Key	0001851657
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	001-41058
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	86-2083865
Entity Address, Address Line One	1717 Main St,
Entity Address, Address Line Two	Ste 3388
Entity Address, City or Town	Dallas
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	75201
City Area Code	254
Local Phone Number	244-5739
Title of 12(b) Security	Class A Common Stock, par value $0.0001 per share
Trading Symbol	VAXX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Class A Common Stock [Member]
Entity Listings [Line Items]
Entity Common Stock, Shares Outstanding		111,519,983
Class B Common Stock [Member]
Entity Listings [Line Items]
Entity Common Stock, Shares Outstanding		13,874,132

Condensed Combined Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 89,375	$ 31,143
Accounts receivable		26
Amounts due from related parties	380	361
Prepaid expenses and other current assets	14,299	4,144
Total current assets	104,054	35,674
Deferred offering costs	6,189	2,254
Property and equipment, net	11,382	12,158
Licensed intellectual property, net	13,217
Restricted cash	74	55
Total assets	134,916	50,141
Current liabilities:
Accounts payable	3,905	1,017
Amounts due to related parties	21,216	8,004
Accrued expense and other current liabilities	5,134	610
Notes payable	425	619
Notes payable with related parties		2,294
Convertible notes payable		10,356
Convertible notes with related parties, net of discount		14,324
Total current liabilities	30,680	37,224
Other liabilities
Simple agreement for future equity		24,335
Notes payable	10,366	10,699
Warrant liability		400
Other long-term liabilities	240	2,383
Total liabilities	41,286	75,041
Commitments and contingencies (Note 14)
Convertible preferres stock	250,997	62,475
Stockholder's deficit:
Common stock	255	272
Treasury stock, par value of $0.0001, 3,169,093 shares and 0 shares at December 31, 2020 and September 30, 2021		(23)
Additional paid-in capital	23,668	4,682
Accumulated deficit	(181,290)	(92,306)
Total stockholders' deficit	(157,367)	(87,375)
Total liabilities, convertible preferred stock, and stockholders' deficit	134,916	50,141
Series Seed Stock [Member]
Other liabilities
Convertible preferres stock		10,383
Series Seed-1 Stock [Member]
Other liabilities
Convertible preferres stock		20,903
Series Seed-2 Stock [Member]
Other liabilities
Convertible preferres stock		11,315
Series A-1 Stock [Member]
Other liabilities
Convertible preferres stock		4,640
Series A-2 Stock [Member]
Other liabilities
Convertible preferres stock		$ 15,234
Series A Preferred Stock [Member]
Other liabilities
Convertible preferres stock	128,206
Series B Preferred Stock [Member]
Other liabilities
Convertible preferres stock	$ 122,791

Condensed Combined Consolidated Balance Sheets (Parenthetical)	Sep. 30, 2021 shares
Common stock, shares authorized	170,650,960
Class A Common Stock [Member]
Common stock, shares authorized	146,477,113
Common Class B [Member]
Common stock, shares authorized	24,173,847

Condensed Combined Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Condensed Combined Consolidated Statements of Operations [Abstract]
Revenue	$ 50	$ 117	$ 67	$ 557
Cost of revenue	9	(178)	1,937	52
Gross profit/loss	41	295	(1,870)	505
Operating expenses:
Research and development	23,616	7,867	54,221	12,109
General and administrative	6,700	5,122	21,130	9,453
Total operating expenses	30,316	12,989	75,351	21,562
Loss from operations	(30,275)	(12,694)	(77,221)	(21,057)
Other expense:
Interest expense, net	109	331	493	737
Change in fair value of convertible notes		2,786	2,667	4,781
Change in fair value of warrant liability			214
Change in fair value of simple agreement for future equity		615	8,365
Foreign currency loss, net	5	39	24	48
Other expense, net	114	3,771	11,763	6,181
Net loss	$ (30,389)	$ (16,465)	$ (88,984)	$ (27,238)
Net loss per share, basic and diluted	$ (0.44)	$ (0.24)	$ (1.30)	$ (0.47)
Weighted average common shares outstanding, basic and diluted	68,728,509	68,138,651	68,667,682	58,154,956

Condensed Combined Consolidated Statements of Stockholders' Deficit - USD ($) $ in Thousands	Total	Series A Preferred Stock [Member]	Common Stock [Member]	Common Stock [Member] Class A Common Stock [Member]	Common Stock [Member] Class B Common Stock [Member]	Preferred Stock [Member]	Preferred Stock [Member] Series Seed Stock [Member]	Preferred Stock [Member] Series Seed-1 Stock [Member]	Preferred Stock [Member] Series Seed-2 Stock [Member]	Preferred Stock [Member] Series A-1 Stock [Member]	Preferred Stock [Member] Series A-2 Stock [Member]	Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member] Series A Preferred Stock [Member] SAFEs [Member]	Preferred Stock [Member] Series A Preferred Stock [Member] Warrants [Member]	Preferred Stock [Member] Series A Preferred Stock [Member] Convertible Debt [Member]	Preferred Stock [Member] Series A Preferred Stock [Member] Notes Payable, Related Parties [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Treasury Stock [Member]	Additional Paid In Capital [Member]	Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2019	$ (48,510)		$ 270	$ 0	$ 0	$ 26,819	$ 10,383	$ 16,436	$ 0	$ 0	$ 0							$ (23)	$ 3,591	$ (52,348)
Beginning balance, common shares at Dec. 31, 2019			37,953,692	0	0
Beginning balance, preferred shares at Dec. 31, 2019							7,831,528	8,017,771	0	0	0
Beginning balance, treasury shares at Dec. 31, 2019																		3,169,093
Issuance of common stock upon exercise of stock options, shares			213,271	68,069
Issuance of common stock upon exercise of stock options	79																		79
Issuance of stock, shares			33,001,476					14,858,686	14,152,237		6,307,690
Issuance of stock								$ 4,467	$ 10,955		$ 15,275
Conversion of stock, shares									463,162
Conversion of stock									$ 360
Vesting of restricted stock, shares			121,282
Vesting of restricted stock	1		$ 1
Stock-based compensation expense	695																		695
Reclassification of common stock to Class A, shares			60,290,572	60,290,572
Reclassification of common stock to Class A			$ (271)	$ 271
Reclassification of common stock to Class B, shares			10,999,149		10,999,149
Net loss	(27,238)																			(27,238)
Ending balance at Sep. 30, 2020	(74,973)		$ 0	$ 271	$ 0	61,863	$ 10,383	$ 20,903	$ 11,315	$ 3,987	$ 15,275							$ (23)	4,365	(79,586)
Ending balance, common shares at Sep. 30, 2020			0	60,358,641	10,999,149
Ending balance, preferred shares at Sep. 30, 2020							7,831,528	22,876,457	14,615,399	1,566,153	6,307,690
Ending balance, treasury shares at Sep. 30, 2020																		3,169,093
Beginning balance at Jun. 30, 2020	(58,818)		$ 271	$ 0	$ 0	42,601	$ 10,383	$ 20,903	$ 11,315	$ 0	$ 0							$ (23)	4,055	(63,121)
Beginning balance, common shares at Jun. 30, 2020			71,289,721	0	0
Beginning balance, preferred shares at Jun. 30, 2020							7,831,528	22,876,457	14,615,399	0	0
Beginning balance, treasury shares at Jun. 30, 2020																		3,169,093
Issuance of common stock upon exercise of stock options, shares				68,069
Issuance of common stock upon exercise of stock options	19																		19
Issuance of stock, shares										1,566,153
Issuance of stock										$ 3,987
Conversion of stock, shares											6,307,690
Conversion of stock											$ 15,275
Stock-based compensation expense	291																		291
Reclassification of common stock to Class A, shares			60,290,572	60,290,572
Reclassification of common stock to Class A			$ (271)	$ 271
Reclassification of common stock to Class B, shares			10,999,149		10,999,149
Net loss	(16,465)																			(16,465)
Ending balance at Sep. 30, 2020	(74,973)		$ 0	$ 271	$ 0	61,863	$ 10,383	$ 20,903	$ 11,315	$ 3,987	$ 15,275							$ (23)	4,365	(79,586)
Ending balance, common shares at Sep. 30, 2020			0	60,358,641	10,999,149
Ending balance, preferred shares at Sep. 30, 2020							7,831,528	22,876,457	14,615,399	1,566,153	6,307,690
Ending balance, treasury shares at Sep. 30, 2020																		3,169,093
Beginning balance at Dec. 31, 2020	(87,375)		$ 0	$ 272		62,475	$ 10,383	$ 20,903	$ 11,315	$ 4,640	$ 15,234	$ 0					$ 0	$ (23)	4,682	(92,306)
Beginning balance, common shares at Dec. 31, 2020			10,999,149	60,360,523
Beginning balance, preferred shares at Dec. 31, 2020							7,831,528	22,876,457	14,615,399	1,871,511	6,307,690	0					0
Beginning balance, treasury shares at Dec. 31, 2020																		3,169,093
Issuance of common stock upon exercise of stock options, shares				82,696
Issuance of common stock upon exercise of stock options	70			$ 6															64
Issuance of stock, shares				485,830						1,566,153							15,365,574
Issuance of stock						122,791				$ 3,987							$ 122,791
Exchange of preferred stock, shares							(7,831,528)	(22,876,457)	(14,615,399)	(1,871,511)	(6,307,690)	53,502,585
Exchange of preferred stock						0	$ (10,383)	$ (20,903)	$ (11,315)	$ (4,640)	$ (15,234)	$ 62,475
Conversion of stock, shares											6,307,690		4,539,060	134,106	3,624,114	423,230
Conversion of stock											$ 15,275		$ 35,600	$ 614	$ 27,379	$ 2,138
Exercise of warrants	13,320																		13,320
Vesting of restricted stock, shares				15,405
Retirement of treasury stock upon merger, shares				(3,169,093)														3,169,093
Retirement of treasury stock upon merger				$ (23)														$ 23
Stock-based compensation expense	5,602																		5,602
Reclassification of common stock to Class B, shares			2,874,983	2,874,985
Net loss	(88,984)																			(88,984)
Ending balance at Sep. 30, 2021	$ (157,367)		$ 0	$ 255		250,997	$ 0	$ 0	$ 0	$ 0	$ 0	$ 128,206					$ 122,791	$ 0	23,668	(181,290)
Ending balance, common shares at Sep. 30, 2021			13,874,132	54,900,376
Ending balance, preferred shares at Sep. 30, 2021	77,588,669	62,223,095					0	0	0	0	0	62,223,095					15,365,574
Ending balance, treasury shares at Sep. 30, 2021																		0
Beginning balance at Jun. 30, 2021	$ (141,821)		$ 0	$ 255		251,049						$ 128,206					$ 122,843		8,825	(150,901)
Beginning balance, common shares at Jun. 30, 2021			13,874,132	54,845,535
Beginning balance, preferred shares at Jun. 30, 2021												62,223,095					15,365,574
Issuance of common stock upon exercise of stock options, shares				54,841
Issuance of common stock upon exercise of stock options	59																		59
Exercise of warrants	13,320																		13,320
Stock-based compensation expense	1,464																		1,464
Additional issuance costs of preferred stock						52
Net loss	(30,389)																			(30,389)
Ending balance at Sep. 30, 2021	$ (157,367)		$ 0	$ 255		$ 250,997	$ 0	$ 0	$ 0	$ 0	$ 0	$ 128,206					$ 122,791	$ 0	$ 23,668	$ (181,290)
Ending balance, common shares at Sep. 30, 2021			13,874,132	54,900,376
Ending balance, preferred shares at Sep. 30, 2021	77,588,669	62,223,095					0	0	0	0	0	62,223,095					15,365,574
Ending balance, treasury shares at Sep. 30, 2021																		0

Condensed Combined Consolidated Statements of Stockholders' Deficit (Parenthetical) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Series Seed-1 Stock [Member]
Issuance of stock, issuance costs			$ 18
Series Seed-2 Stock [Member]
Issuance of stock, issuance costs			45
Series A-1 Stock [Member]
Issuance of stock, issuance costs	$ 585		373
Series A-2 Stock [Member]
Issuance of stock, issuance costs	$ 41		$ 41
Series B Preferred Stock [Member]
Issuance of stock, issuance costs		$ 133

Condensed Combined Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities:
Net loss	$ (88,984)	$ (27,238)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	928	363
Stock-based compensation expense	5,602	695
Non-cash interest expense	268	405
Change in fair value of convertible notes	2,667	4,781
Change in fair value of warrant liability	214
Change in fair value of simple agreement for future equity	8,365
Changes in operating assets and liabilities:
Accounts receivable	26	(26)
Prepaid expenses and other current assets	(10,155)	(5,296)
Amounts due from related parties	(18)	(34)
Deferred offering costs	(3,935)	(541)
Accounts payable	2,888	821
Amounts due to related parties	13,212	2,177
Accrued expenses and other current liabilities	4,521	487
Other liabilities	(2,625)	122
Net cash used in operating activities	(67,026)	(22,669)
Cash flows from investing activities:
Purchase of property and equipment	(50)	(1,026)
Net cash used in investing activities	(50)	(1,026)
Cash flows from financing activities:
Proceeds from issuance of convertible notes payable	2,000	12,040
Payment of debt issuance costs for related party convertible notes		(300)
Repayment of convertible notes	(2,096)	(5,500)
Proceeds from issuance of simple agreement for future equity	2,900	15,020
Repayment of note payable with related party	(100)
Proceeds and repayments Paycheck Protection Program	(257)	257
Proceeds from exercise of stock options	70	79
Net cash provided by financing activities	125,308	41,378
Increase in cash, cash equivalents, and restricted cash	58,232	17,683
Cash and cash equivalents at beginning of period	31,143	476
Restricted Cash	74	79
Cash, cash equivalents and restricted cash at end of period	89,449	18,238
Supplemental disclousres of non-cash investing, financing and cash flow information:
Non cash interest expense	268	425
Fair value of restricted stock vesting during the period		1
Acquisition of airplane through isuance of note payable		11,500
Issue of Warrant for Licensed Intellectual Property	13,320
Fair Value of Warrant	630
Series Seed-1 Stock [Member]
Cash flows from financing activities:
Proceeds from issuance of convertible preferred stock, net of issuance costs		4,467
Series Seed-2 Stock [Member]
Cash flows from financing activities:
Proceeds from issuance of convertible preferred stock, net of issuance costs		10,955
Supplemental disclousres of non-cash investing, financing and cash flow information:
Conversion of simple agreement for future equity into Series preferred stock		360
Series A-1 Stock [Member]
Cash flows from financing activities:
Proceeds from issuance of convertible preferred stock, net of issuance costs		4,360
Series A-2 Stock [Member]
Supplemental disclousres of non-cash investing, financing and cash flow information:
Conversion of simple agreement for future equity into Series preferred stock		15,275
Series B Preferred Stock [Member]
Cash flows from financing activities:
Proceeds from issuance of convertible preferred stock, net of issuance costs	$ 122,791
Supplemental disclousres of non-cash investing, financing and cash flow information:
Fair Value of Warrant		$ 373

Nature of the Business	9 Months Ended
Nature of the Business	Sep. 30, 2021
Nature of the Business [Abstract]
Nature of the Business	1. Nature of the Business Vaxxinity, Inc., a Delaware corporation (“Vaxxinity”, and together with its subsidiaries, the “Company”), was formed through the combination of two separate businesses that originated from United Biomedical, Inc. (“UBI”) in two separate transactions: a spin-out from UBI in 2014 of operations focused on developing chronic disease product candidates that resulted in United Neuroscience (“UNS”), and a second spin-out from UBI in 2020 of operations focused on the development of a COVID-19 vaccine that resulted in C19 Corp. (“COVAXX”). On February 2, 2021, Vaxxinity was incorporated for the purpose of reorganizing and combining UNS and COVAXX and on March 2, 2021, did so by acquiring all the outstanding equity interests of UNS and COVAXX pursuant to a contribution and exchange agreement (the “Contribution and Exchange Agreement”) whereby the existing equity holders of UNS and COVAXX contributed their equity interests in each of UNS and COVAXX in exchange for equity in Vaxxinity (the “Reorganization”). The Company is a biotechnology company currently focused on developing product candidates for human use in the fields of neurology and coronaviruses utilizing its “Vaxxine Platform” — a peptide vaccine technology first developed by UBI and subsequently refined over the last two decades. The Company is engaged in the development and commercialization of rationally designed prophylactic and therapeutic vaccines to combat chronic disorders and infectious diseases with large patient populations and unmet medical need. UBI is a significant shareholder of the Company and, therefore, considered a related party. Impact of COVID-19 Pandemic In March 2020, the World Health Organization declared the outbreak of a COVID-19 pandemic. The COVID-19 pandemic is evolving, and to date, has led to the implementation of various responses, including government-imposed quarantines, travel restrictions and other public health safety measures. The Company is closely monitoring the impact of the COVID-19 pandemic on all aspects of its business, including how it will impact its operations and the operations of its customers, suppliers, vendors and business partners. The Company does not yet know the full extent of potential delays or impacts on its business, its clinical trials, its research programs, healthcare systems or the global economy and it cannot presently predict the scope and severity of any potential business shutdowns or disruptions. The extent to which COVID-19 impacts its business, results of operation and financial condition will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, new information that may emerge concerning the severity of COVID-19 or the effectiveness of actions to contain COVID-19 or treat its impact, among others. If the Company or any of the third parties with whom the Company engages, however, were to experience shutdowns or other business disruptions, its ability to conduct its business in the manner and on the timelines presently planned could be materially and negatively affected, which could have a material adverse impact on its business, results of operation and financial condition. The Company has not incurred impairment losses in the carrying values of its assets as a result of the COVID-19 pandemic and it is not aware of any specific related event or circumstance that would require it to revise its estimates reflected in these condensed combined consolidated financial statements.

Summary of Significant Accounting Policies	9 Months Ended
Summary of Significant Accounting Policies	Sep. 30, 2021
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited interim condensed combined consolidated financial statements have been prepared pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial reporting. The condensed consolidated financial statements for the periods presented include the accounts of UNS and COVAXX that were parties to the Contribution and Exchange Agreement. All share and per share amounts, as originally recorded by each entity, have been converted to a number of shares and per share amounts using the conversion ratios determined under the Contribution and Exchange Agreement. These interim condensed combined consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting of normal recurring adjustments and accruals) necessary to fairly present the results of the interim periods. The condensed combined balance sheet at December 31, 2020, has been derived from the audited financial statements at that date. Operating results for the three and nine months ended September 30, 2021 and cash flows for the nine months ended September 30, 2021 are not necessarily indicative of the results that may be expected for the fiscal year ended December 31, 2021 or any other future period. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been omitted in accordance with the rules and regulations for interim reporting of the SEC. These interim condensed financial statements should be read in conjunction with the financial statements and notes thereto included in our report for the year ended December 31, 2020. Significant Accounting Policies The significant accounting policies used in preparation of these condensed financial statements are disclosed in our annual financial statements for the year ended December 31, 2020. There have been no changes to the Company’s significant accounting policies during the three and nine months ended September 30, 2021. Emerging Growth Company Status The Company is an “emerging growth company” (“EGC”), as defined in the Jumpstart Our Business Startups Act (“JOBS Act”) and is permitted to and plans to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. The Company may take advantage of these exemptions until it is no longer an EGC under Section 107 of the JOBS Act, which provides that an EGC can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to avail itself of the extended transition period and, therefore, while the Company is an EGC it will not be subject to new or revised accounting standards at the same time that they become applicable to other public companies that are not EGCs. Recently Adopted Accounting Pronouncements In November 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 , (“ASU 2018-18”). The amendments in this update clarify that certain transactions between collaborative arrangement participants should be accounted for as revenue when the collaborative arrangement participant is a customer in the context of a unit of account and precludes recognizing as revenue consideration received from a collaborative arrangement participant if the participant is not a customer. ASU 2018-18 is effective for the Company’s annual reporting periods after December 15, 2020. The Company adopted ASU 2018-18 at January 1, 2021. The adoption of this pronouncement did not have a material impact on the Company’s combined consolidated financial statements or its results of operations. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The new standard will be effective for the Company beginning January 1, 2021. The Company adopted ASU 2019-12 at January 1, 2021. The adoption of this pronouncement did not have a material impact on the Company’s combined consolidated financial statements or its results of operations. Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU 2016-12, “Leases (Topic 842), and associated ASUs related to Topic 842, which requires organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. The new guidance requires that a lessee recognize assets and liabilities for leases, and recognition, presentation and measure in the financial statements will depend on its classification as a finance or operating lease. In addition, the new guidance requires disclosures to help investors and other financial statement users better understand the amount, timing and uncertainty of cash flows arising from leases. The estimated impact on our existing lease agreements is approximately $ 250,000 . The Company has elected to apply the transition requirements as of January 1, 2022. This approach allows for a cumulative effect adjustment in the period of adoption, and prior periods continue to be reported in accordance with historic accounting under ASC 840 “Leases.” Additionally, as an accounting policy election, the Company has chosen to not apply the standard to any existing short-term leases (term of 12 months or less) as this is optional under U.S. GAAP.

Fair Value Measurements	9 Months Ended
Fair Value Measurements	Sep. 30, 2021
Fair Value Measurements [Abstract]
Fair Value Measurements	3. Fair Value Measurements The value for the Convertible Notes, SAFE and warrant liability balances as of December 31, 2020 are based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. In accordance with the Contribution and Exchange Agreement, on March 2, 2021 the Convertible Notes, SAFEs and warrants were all converted into Series A preferred stock. The following tables present information about the Company’s financial instruments measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values: December 31, 2020 Level 1 Level 2 Level 3 Total Liabilities Convertible notes payable $ — $ — $ 24,040 $ 24,040 SAFEs — — 24,335 24,335 Warrant liability — — 400 400 $ — $ — $ 48,775 $ 48,775 September 30, 2021 Level 1 Level 2 Level 3 Total Assets Money market funds $ 84,000 $ — $ — $ 84,000 $ 84,000 $ — $ — $ 84,000 During the nine months ended September 30, 2020 and 2021, there were no transfers between Level 1, Level 2 and Level 3. Convertible Notes During the years ended December 31, 2019 and 2020, and the nine months ended September 30, 2021, the Company issued Convertible Notes. In accordance with ASC 480, a portion of the Convertible Notes were required to be measured and accounted for at fair value at each reporting date. The Company determined the Convertible Notes requiring a measurement to fair value represent a recurring measurement that is classified within Level 3 of the fair value hierarchy wherein fair value is estimated using significant unobservable inputs. Convertible Notes requiring a measurement to fair value are as follows (in thousands): The fair value of the Convertible Notes was estimated using a straight debt and conversion feature valuation model consisting of probability assumptions on multiple conversion scenarios, discount rates and interest rates. In accordance with the Contribution and Exchange Agreement, on March 2, 2021, the Convertible Notes were converted into Series A preferred stock. Simple Agreement for Future Equity During the year ended December 31, 2020, the Company executed SAFE arrangements. The fair value of the SAFEs on the date of issuance was determined to equal the proceeds received by the Company. The value of the SAFEs on the dates of conversion into preferred stock was determined to be equal to the fair value of the preferred stock issued, or $ 15.6 million. The following table sets forth a summary of the activities of the SAFE arrangements, which represents a recurring measurement that is classified within Level 3 of the fair value hierarchy wherein fair value is estimated using significant unobservable inputs (in thousands): In accordance with the Contribution and Exchange Agreement, on March 2, 2021, the SAFEs were converted into Series A preferred stock. Warrants to Purchase Series A-1 Convertible Preferred Stock & Common Stock In connection with the 2020 Series A-1 convertible preferred stock (“Series A-1 preferred”) financing transactions, the Company issued fully vested warrants to purchase 205,970 shares of Series A-1 preferred. The warrants were issued to advisors as consideration for assistance with the sale and issuance of the Series A-1 preferred. The warrants were determined to represent issuance costs and were recorded as a reduction in the proceeds received from the sale. The warrants were issued to advisors of the company and represented non-variable contingently redeemable instruments. As such, the warrants were accounted for as liabilities and adjusted to fair value at each reporting period. The warrants are exercisable on the date of issuance and have an exercise price of $ 0.003 per share and a contractual term of ten years . In December 2020, 71,862 warrants were exercised at $ 0.003 per share, resulting in cash proceeds of less than $ 1,000 . As of December 31, 2020, 134,106 warrants to purchase Series A-1 preferred were outstanding. The Company continued to re-measure the fair value of the liability associated with the warrant to purchase shares of Series A-1 preferred at the end of each reporting period until the Reorganization, when the warrant converted into Series A preferred stock and subsequently, in connection with the IPO, converted into Class A common stock. The following table sets forth a summary of the activity of the warrant liability which represented a recurring measurement that is classified within Level 3 of the fair value hierarchy wherein fair value is estimated using significant unobservable inputs (in thousands): September 30, 2021 Beginning balance, December 31, 2020 $ 24,680 Level 3 fair value of the principal amount of convertible notes $ 24,040 Change in fair value 2,667 Conversion to Series A preferred stock (26,707) Ending balance September 30, 2021 $ — SAFE Liability Balance at December 31, 2020 $ 24,335 Change in fair value 8,365 Issuance of SAFEs 2,900 Conversion to Series A preferred stock (35,600) Balance at September 30, 2021 $ — Warrants Liability Balance at December 31, 2020 $ 400 Change in fair value 214 Exchange of warrants for shares of Series A preferred stock (614) Balance at September 30, 2021 $ — On August 5, 2021, as partial consideration for the rights and licenses the company received pursuant to the Platform License Agreement, the company issued a warrant to United Biomedical, Inc., for the purchase of 1,928,020 shares of Class A common stock at an exercise price of $ 12.45 per share. The fair value of this warrant as of September 30, 2021 was $ 13.3 million. Due to its underlying characteristics, the warrant was classified as additional paid in capital with a corresponding recognition as an ‘intangible asset - licensed intellectual property’ to be amortized over its estimated useful life of twenty years .

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Property, Equipment and Licensed Intellectual Property	9 Months Ended
Property, Equipment and Licensed Intellectual Property	Sep. 30, 2021
Property, Equipment and Licensed Intellectual Property [Abstract]
Property, Equipment and Licensed Technology	4. Property, Equipment and Licensed Intellectual Property Property and equipment, net consisted of the following (in thousands): December 31, September 30, 2020 2021 Airplane $ 11,983 $ 11,983 Laboratory and computer equipment 969 1,019 Furniture and fixtures 84 84 Total property and equipment $ 13,036 $ 13,086 Less accumulated depreciation (878) (1,704) Property and equipment, net $ 12,158 $ 11,382 Depreciation and amortization expense for the three and nine months ended September 30, 2020 was less than $ 0.1 million and less than $ 0.1 million respectively. Depreciation and amortization expense for the three and nine months ended September 30, 2021 was $ 0.4 million and $ 0.9 million, respectively. Licensed intellectual property, net consisted of the following (in thousands): Licensed intellectual property is amortized over the estimated lifetime of the intangible asset ( 20 years). As of September 30, 2021, the annual amortization schedule is as follows (in thousands): September 30, 2021 Licensed intellectual property $ 13,320 Less accumulated amortization (103) Licensed intellectual property, net $ 13,217 Amount 2021 (Q4 2021) $ 167 2022 666 2023 666 2024 668 2025 and thereafter 11,050 $ 13,217

Accrued Expenses and Other Current Liabilities	9 Months Ended
Accrued Expenses and Other Current Liabilities	Sep. 30, 2021
Accrued Expenses and Other Current Liabilities [Abstract]
Accrued Expenses and Other Current Liabilities	5. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following (in thousands): December 31, September 30, 2020 2021 Accrued professional fees and other 228 2,240 Accrued payroll and benefits 53 2,138 Accrued interest 33 31 Accrued external research and development 296 725 $ 610 5,134

Convertible Notes Payable	9 Months Ended
Convertible Notes Payable	Sep. 30, 2021
Notes Payable [Abstract]
Convertible Notes Payable	6. Convertible Notes Payable Beginning in April 2018, the Company issued several Convertible Notes, some of which were issued to related parties. The Convertible Notes bear simple interest at annual rates ranging from 4.8 % to 6 %. All unpaid principal, together with the accrued interest thereon, are payable upon an event of default or upon maturity, which ranges from one to three years . The Convertible Notes contain a number of provisions addressing automatic and optional conversion, events of default, and prepayment provisions. The Company accounts for the Convertible Notes at fair value, in accordance with ASC 480, with any changes in fair value being recognized through the condensed combined consolidated statements of operations. In accordance with the Contribution and Exchange Agreement, on March 2, 2021 each Reorg. Convertible Note (as defined below) that was outstanding was exchanged for shares of Series A preferred stock, as set forth in the applicable Convertible Note agreements and the Contribution and Exchange Agreement. During the three and nine months ended September 30, 2021, the Company recognized interest expense of $ 0.1 and $ 0.2 million, respectively, related to the Convertible Notes. In addition, during the nine months ended September 30, 2021, the Company recognized a change in fair value of $ 2.7 million in the accompanying condensed combined consolidated statements of operations related to the Convertible Notes. The following table shows the activity of the Convertible Notes (in thousands): Convertible Notes Principal Amount Payable Change in Fair Value Accrued Interest Issuance Conversion to Standard Related Party Standard Related Party Standard Related Party Costs Series A Preferred Balance December 31, 2019 $ 11,170 $ 510 $ 33 $ 26 $ 378 $ 4 $ — $ — $ 12,121 Additions 2,040 10,000 1,661 3,119 203 48 (300) 16,771 Settlements (5,500) — — — — — (5,500) September 30, 2020 $ 7,710 $ 10,510 $ 1,694 $ 3,145 $ 581 $ 52 $ (300) $ — $ 23,392 Convertible Notes Principal Amount Payable Change in Fair Value Accrued Interest Issuance Conversion to Standard Related Party Standard Related Party Standard Related Party Costs Series A Preferred Balance December 31, 2020 $ 7,710 $ 10,510 $ 1,972 $ 3,848 $ 674 $ 183 $ (217) $ — $ 24,680 Additions — 2,000 812 1,855 48 121 — — 4,836 Settlements (2,000) — — — (187) — — — (2,187) Amortization — — — — — — 50 — 50 Conversion of Convertible Notes to Series A preferred stock — — — — — — 167 (27,546) (27,379) September 30, 2021 $ 5,710 12,510 $ 2,784 $ 5,703 $ 535 $ 304 $ — $ (27,546) $ —

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

Notes Payable	9 Months Ended
Notes Payable	Sep. 30, 2021
Notes Payable [Abstract]
Notes Payable	7. Notes Payable Notes Payable with Related Parties In December 2018, the Company entered into related party convertible notes payable (the “2018 Related Notes” and together with the Convertible Notes, the “Reorg. Convertible Notes”) for $ 2.0 million in aggregate proceeds, received in three tranches. The 2018 Related Notes bore simple interest at an annual rate of 5 % and contain a number of provisions addressing automatic and optional conversion, events of default and prepayment. In accordance with the Contribution and Exchange Agreement, on March 2, 2021, the 2018 Related Notes were converted into Series A preferred stock. In November 2019, the Company borrowed $ 0.1 million from its Chief Executive Officer (the “2019 Executive Note”). No formal loan agreement was executed. However, the Company has elected to accrue interest at an annual rate of 5 %, consistent with the terms and conditions of the Convertible Notes and 2018 Related Notes, which was the closest benchmark the Company could evaluate. The 2019 Executive Note was repaid in August 2021. Note Payable—Airplane In connection with the acquisition of an airplane, the Company entered into a note payable agreement (the “2025 Note”) in June 2020 for $ 11.5 million, with an annual interest rate of 3.4 % and a maturity date of June 9, 2025 . Principal and interest payments are payable monthly in the amount of $ 0.06 million with a final payment of $ 9.4 million at maturity. The 2025 Note is guaranteed by the co-founders of the Company. In addition, the Company incurred debt issuance costs of $ 0.3 million, which are being amortized over the term of the loan. There are no financial covenants associated with the 2025 Note. The carrying value of the 2025 Note is as follows (in thousands): September 30, 2021 Principal $ 10,989 Unamortized debt issuance cost (198) Carrying amount 10,791 Less: current portion (425) Note payable, net of current portion and debt issuance cost $ 10,366 As of September 30, 2021, the remaining principal payments for the 2025 Note, are as follows (in thousands): Amount 2021 $ 105 2022 429 2023 444 2024 458 2025 and thereafter 9,553 $ 10,989 Interest expense associated with the 2025 Note was less than $ 0.1 million for each of the three and nine months ended September 30, 2020. Interest expense associated with the 2025 Note was $ 0.1 million and $ 0.3 million for the three and nine months ended September 30, 2021. Note Payable—Paycheck Protection Program The Company applied for and received a loan, which is in the form of a note dated May 5, 2020, from HSBC Bank USA, National Association (“HSBC”) in the aggregate amount of approximately $ 0.3 million (the “PPP Loan”), pursuant to the Paycheck Protection Program (“PPP”). The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”), provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. As of December 31, 2020, there were no events of default under the PPP Loan. The Company paid off the PPP Loan in full, including all accrued but unpaid interest to the repayment date, in August 2021.

Convertible Preferred Stock	9 Months Ended
Convertible Preferred Stock	Sep. 30, 2021
Convertible preferred stock [Abstract]
Convertible preferred stock	8. Convertible Preferred Stock As explained in Note 1, in accordance with the Contribution and Exchange Agreement, on March 2, 2021 each share of preferred stock of UNS and COVAXX, as well as each Reorg. Convertible Note, that was outstanding was exchanged for Vaxxinity’s preferred stock as set forth in the Contribution and Exchange Agreement. Each UNS convertible preferred share was exchanged for 0.2191 shares of Vaxxinity preferred stock and each share of COVAXX convertible preferred stock was exchanged for 3.4233 shares of Vaxxinity preferred stock. As of September 30, 2021, Vaxxinity’s Amended and Restated Certificate of Incorporation (authorized 87,223,095 shares of convertible preferred stock with a par value of $ 0.0001 per share, of which 62,223,095 shares have been designated as Series A preferred stock and 25,000,000 shares have been designated as Series B preferred stock. The holders of Vaxxinity’s preferred stock have liquidation rights in the event of a deemed liquidation that, in certain situations, are not solely within the control of Vaxxinity. Therefore, the preferred stock is classified outside of stockholders’ deficit. Preferred stock consisted of the following as of September 30, 2021: As of September 30, 2021 Issuance Dates Shares issued and outstanding Common Stock Issuable Upon Conversion Series A preferred stock March 2021 62,223,095 39,989,083 Series B preferred stock March 2021 5,441,863 3,497,337 Series B preferred stock June 2021 9,923,711 6,377,700 77,588,669 49,864,120 The common stock issuable upon conversion reflects the application of the stock split described in Note 1. All shares of preferred stock were automatically converted into shares of Vaxxinity’s Class A common stock concurrently with the closing of the Company’s IPO in November 2021.

Simple Agreement for Future Equity	9 Months Ended
Simple Agreement for Future Equity	Sep. 30, 2021
Simple Agreement for Future Equity [Abstract]
Simple Agreement for Future Equity	9. Simple Agreement for Future Equity During the year ended December 31, 2020, the Company executed SAFE arrangements. The SAFEs were not mandatorily redeemable, nor did they require the Company to repurchase a fixed number of shares. The Company determined that the SAFEs contained a liquidity event provision that embodied an obligation indexed to the fair value of the Company’s equity shares and could require the Company to settle the SAFE obligation by transferring assets or cash. For this reason, the Company recorded the SAFEs as a liability under ASC 480 and re-measured the fair value at the end of each reporting period, with changes in fair value reported in earnings. In March 2020, the Company issued a SAFE (“SAFE 1”) for $ 0.4 million, which converted into 463,162 shares of Series Seed-2 convertible preferred stock at $ 0.7773 per share in April 2020. In June, July, and August 2020, the Company issued a series of SAFEs (“SAFE 2”) for $ 14.7 million, which converted into 6,307,690 shares of Series A-2 convertible preferred stock (“Series A-2 preferred”) at $ 2.3241 per share in August 2020. The Company determined the fair value of SAFE 2 investment on the date of conversion and recognized the difference between the fair value on the date of conversion and the initial fair value of SAFE 2 investment in the consolidated statement of operations. A loss of $0.6 million was recorded in the consolidated statement of operations for the nine months ended September 30, 2020. In December 2020, the Company issued a series of SAFEs (collectively, “SAFE 3”) for $ 24.3 million. In January 2021, the Company issued additional SAFEs for $ 2.9 million. As explained in Note 1, in accordance with the Contribution and Exchange Agreement, on March 2, 2021, the shareholders of both UNS and COVAXX contributed their capital stock in exchange for Vaxxinity’s capital stock. Prior to the Reorganization, all the holders of outstanding COVAXX SAFEs agreed to convert such SAFEs into shares of Series A-3 preferred stock of COVAXX, which shares were then exchanged for shares of the Company’s Series A preferred stock.

Common Stock	9 Months Ended
Common Stock	Sep. 30, 2021
Common Stock [Abstract]
Common Stock	10. Common Stock As explained in Note 1, in accordance with the Contribution and Exchange Agreement, on March 2, 2021, all outstanding shares of common stock of UNS and COVAXX were contributed to Vaxxinity and exchanged for an aggregate of 57,702,458 shares of Vaxxinity’s Class A common stock, 10,999,149 shares of Vaxxinity’s Class B common stock and 37,388,014 shares of our Series A preferred was exchanged for Vaxxinity’s common stock. Each UNS share of common stock was exchanged for 0.2191 shares of Vaxxinity common stock and each share of COVAXX common stock was exchanged for 3.4233 like shares of Vaxxinity common stock. In September 2021, the Company converted 2,874,984 shares of Class A common stock held by the Company’s Chief Executive Officer and Executive Chairman on a one -to-one basis for shares of Class B common stock. As of September 30, 2021, Vaxxinity’s Amended and Restated Certificate of Incorporation authorized 170,650,960 shares of common stock with a par value of $ 0.0001 per share, of which 146,477,113 shares have been designated as Class A common stock and 24,173,847 shares have been designated as Class B common stock. Holders of Class A common stock and Class B common stock have identical rights, except with respect to voting and conversion. Except as otherwise expressly provided in Vaxxinity’s Amended and Restated Certificate of Incorporation or Bylaws, or required by applicable law, holders of Class A common stock will be entitled to one vote per share on all matters submitted to a vote of stockholders and holders of our Class B common stock will be entitled to ten votes per share on all matters submitted to a vote of stockholders. Holders of Class A common stock and Class B common stock vote together as a single class on all matters submitted to a vote of stockholders, except (i) amendments to Vaxxinity’s Amended and Restated Certificate of Incorporation to increase or decrease the par value of a class of capital stock, in which case the applicable class would be required to vote separately to approve the proposed amendment and (ii) amendments to Vaxxinity’s Amended and Restated Certificate of Incorporation that alter or change the powers, preferences or special rights of a class of capital stock in a manner that affects its holders adversely, in which case the applicable class would be required to vote separately to approve the proposed amendment. Holders of common stock are entitled to receive, ratably, dividends as may be declared by Vaxxinity’s board of directors out of funds legally available therefor if the board of directors, in its discretion, determines to issue dividends. The voting, dividend, and liquidation rights of the holders of common stock are subject to and qualified by the rights, powers, and preferences of the holders of Vaxxinity’s preferred stock. The Company has reserved shares of common stock for issuance for the following purposes at September 30, 2021: Series A preferred stock 39,989,083 Series B preferred stock 9,875,037 Options issued and outstanding 20,714,308 Options available for future grants 7,169,027 Warrants issued and outstanding to purchase shares of common 2,056,722 79,804,177

Equity Incentive Plan	9 Months Ended
Equity Incentive Plan	Sep. 30, 2021
Equity Incentive Plan [Abstract]
Equity Incentive Plan	11. Equity Incentive Plan Stock Options In February 2021, the Company replaced the 2017 and 2020 Stock Option and Grant Plans with the newly-adopted 2021 Stock Option and Grant Plan (the “Plan”), which provides for the Company to grant qualified incentive options, nonqualified options, restricted stock awards, unrestricted stock awards, and restricted stock units to employees and non-employees to purchase the Company’s common stock. The maximum number of shares of common stock that can be issued under the Plan is 21,593,830 shares of Class A and 6,362,45 6 Class B shares. As of September 30, 2021, 7,169,027 shares were available for Class A common stock future grant. Shares that are forfeited, canceled, reacquired by the Company prior to vesting, satisfied without the issuance of stock, withheld to cover the exercise price or tax withholdings, or otherwise terminated, other than by exercise, shall be added back to the Shares available for issuance under the Plan. The exercise price for grants made pursuant to the terms of the Plan is determined in the applicable grant by the board of directors. Any incentive options granted to persons possessing less than 10 % of the total combined voting power of all classes of stock may not have an exercise price of less than 100 % of the fair market value of the common stock on the grant date. Any incentive options granted to persons possessing more than 10 % of the total combined voting power of all classes of stock may not have an exercise price of less than 110 % of the fair market value of the common stock on the grant date. The option term for incentive awards may not be greater than ten years from the date of the grant. Incentive options granted to persons possessing more than 10 % of the total combined voting power of all classes of stock may not have an option term of greater than five years from the date of the grant. The vesting period for equity-based awards is determined at the discretion of the board of directors. In August 2021, we canceled existing options to purchase, in aggregate, 6,342,456 shares of our Class A common stock held by Mei Mei Hu and Louis Reese in exchange for an equal number of options to purchase shares of our Class B common stock. The new options to purchase shares of our Class B common stock were issued with exercise prices equal to the fair value of our Class B common stock on the new grant date. The company concluded, due to an increased exercise price in the exchanged options, there will be no associated incremental value reflected in our stock compensation expense. As of September 30, 2021 there were 14,351,853 options for Class A shares outstanding and 6,362,456 options for Class B shares outstanding, of which 7,092,282 Class A shares were exercisable. Total stock-based compensation expense for stock options is as follows (in thousands): Three Months Ended September 30, Nine months ended September 30, 2020 2021 2020 2021 Research and development $ 83 $ 364 $ 206 $ 738 General and administrative 208 1,100 489 4,864 Total stock-based compensation expense $ 291 $ 1,464 $ 695 $ 5,602 Restricted Stock The following table summarizes the Company’s restricted stock activity for the nine months ended September 30, 2021: Number of Shares Weighted average grant date fair value per share Unvested at December 31, 2020 15,405 $ 0.32 Vested (15,405) $ 0.32 Unvested at September 30, 2021 - $ - Stock-based compensation expense recognized on vested restricted stock was immaterial for the three and nine months ended September 30, 2020 and 2021, respectively.

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2021
Income Taxes [Abstract]
Income Taxes	12. Income Taxes During the three and nine months ended September 30, 2020 and 2021, respectively, the Company recorded no income tax benefit for the net operating losses incurred in each year, due its uncertainty of realizing a benefit from those items. The Company’s tax provision and the resulting effective tax rate for interim periods is determined based upon its estimated annual effective tax rate, adjusted for the effect of discrete items arising during the interim quarterly period. The impact of such inclusions could result in a higher or lower effective tax rate during a particular quarterly period, based upon the mix and timing of actual earnings or losses versus annual projections. In each quarterly period, the Company updates its estimate of the annual effective tax rate, and if the estimated annual tax rate changes, a cumulative adjustment is made in that quarter. The Company has evaluated the positive and negative evidence bearing upon its ability to realize its deferred tax assets, which primarily consist of net operating loss carryforwards. The Company has considered its history of cumulative net losses, estimated future taxable income and prudent and feasible tax planning strategies and has concluded that it is more likely than not that the company will not realize the benefits of its deferred tax

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Net Loss Per Share	9 Months Ended
Net Loss Per Share	Sep. 30, 2021
Net Loss Per Share [Abstract]
Net Loss Per Share	13. Net Loss Per Share The Company’s unvested restricted common shares have been excluded from the computation of basic net loss per share. The Company’s potentially dilutive securities, which include options, unvested restricted stock, convertible notes payable and convertible preferred stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share as of September 30, 2021 because including them would have had an anti-dilutive effect: Series A preferred stock 39,989,083 Series B preferred stock 9,875,037 Options to purchase common stock 20,714,308 Warrants issued and outstanding to purchase shares of common stock 2,056,722 72,635,150

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2021
Commitments and Contingencies [Abstract]
Commitments and Contingencies	14. Commitments and Contingencies Contractual Obligations The Company enters into agreements with contract research organizations (“CROs”) to conduct clinical trials and preclinical studies and contract manufacturing organizations (“CMOs”) to produce vaccines and other potential product candidates. Contracts with CROs and CMOs are generally cancellable, with notice, at the Company’s option. As of September 30, 2021, the Company had remaining prepayments to CROs of $ 1.0 million and remaining prepayments to CMOs of $ 10.9 million for activities associated with the conduct of its clinical trials and for the production of the Company’s anticipated vaccine product candidate. Lease Agreements The Company has multiple operating lease agreements for office and laboratory space that extend through August 2022. The Company records total expense on a straight-line basis over the term of the lease agreement. One of the Company’s leases requires the Company to provide a security deposit in the amount of $ 0.02 million. The Company is also required to pay certain operating costs under its leases. Rent expense for each of the three and nine months ended September 30, 2020 was less than $ 0.1 million. Rent expense for each of the three and nine months ended September 30, 2021 was less than $ 0.1 million. In August 2021, the Company entered into a lease for 5,248 square feet of lab space with Space Florida in Exploration Park, Florida commencing August 12, 2021. The lease has an initial one-year term with an annual lease obligation of $ 0.2 million, after Lessee credits. License Agreements In October 2014, the Company entered into a contribution agreement with UBI, whereby UBI contributed and assigned to the Company assets and granted a non-exclusive license to certain technologies deemed necessary or reasonably useful in the utilization of the licensed intellectual property. In consideration, the Company issued 32,505,306 shares of common stock to UBI. The agreement allowed for exploitation of all diagnostic, prophylactic, and therapeutic uses and indications in humans in the field of neurology. The agreement was amended in August 2019 to provide the Company with exclusivity (except as to UBI) in the field of neurology and the flexibility to pursue indications outside the initial field limitations. Details of amended agreement issued in exchange for warrants shown in Note 3. In connection with the amendment, the Company agreed to execute an exclusive, worldwide license agreement for any product that is developed by the Company outside the original field. The terms and conditions are to be negotiated in good faith and mutually agreed upon. The Company anticipates that if it is required to enter into an exclusive license agreement, it will be able to negotiate financial terms for the license at prevailing market rates within the pharmaceutical industry. Accordingly, the Company may be required to pay UBI upfront fees, revenue royalties, development milestones, commercial milestones, sublicense fees, and other related fees. Vaxxinity’s COVAXX subsidiary was formed in March 2020 through a transfer of technology from UBI, UBI IP Holdings, and UBI US Holdings, LLC, all related parties of the Company, whereby the Company, pursuant to an April 2020 license agreement, obtained exclusive rights to intellectual property and technology related to the discovery of vaccines, diagnostic assays, and antigens for use against all coronaviruses including, without limitation, SARS, MERS, and COVID-19 in all strains in humans. The license is worldwide, perpetual, exclusive and fully paid-up. There are no future royalty or milestone payment obligations associated with the agreement. The Company has the right to grant sublicenses. The Company considered ASC 805, “Business Combinations” and ASC 730, “Research and Development” in determining how to account for the issuance of common stock. The license agreement is considered to be a common control transfer; however, the related party did not have any basis in the assets licensed, so there was no accounting impact for the Company. Indemnification Agreements In the ordinary course of business, the Company may provide indemnification of varying scope and terms to employees, consultants, vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations, or cash flows, and it has no t accrued any liabilities related to such obligations as of September 30, 2021. Legal Proceedings From time to time, the Company may become involved in legal proceedings arising in the ordinary course of business. As of September 30, 2021, the Company was not a party to any material legal matters or claims.

Related Party Transactions	9 Months Ended
Related Party Transactions	Sep. 30, 2021
Related Party Transactions [Abstract]
Related Party Transactions	15. Related Party Transactions Pursuant to a Master Services Agreement with UBI (“MSA”), UBI provides research, development and clinical functions to the Company. The Company pays for services provided by UBI based on the UBI costs incurred plus a markup of 7.5 % and reimburses for certain pass-through costs. Total amounts due to UBI pursuant to this MSA were $ 3.6 million and $ 4.0 million, as of December 31, 2020 and September 30, 2021, respectively. Total service fees incurred were $ 0.4 million and less than $ 0.1 million for nine months ended September 30, 2020 and 2021, respectively. The Company also maintains a purchase arrangement with UBI for the production and shipment of the Company’s diagnostic test kits to its customers. The Company has prepaid for materials required in this arrangement and recognizes prepayments as cost of goods sold when UBI ships product containing the materials to the Company’s customers. As of December 31, 2020 and September 30, 2021, $ 2.9 million and $ 1.0 million of diagnostic test kit materials prepaid to UBI are included in ‘Prepaid expenses and other current assets’ in the condensed combined consolidated balance sheets, respectively. The Company is party to an MSA (“MSA Asia”) with United Biomedical, Inc., Asia (“UBI-Asia”) for manufacturing, quality control, testing, validation, and supply services. Payment terms are mutually agreed in connection with each work order relating to services rendered. Total amounts due to UBI-Asia UBI pursuant to this MSA were $ 1.0 and $ 1.1 million as of December 31, 2020 and September 30, 2021, respectively. Total service fees incurred were $ 0.1 million and $ 0.7 million for the nine months ended September 30, 2020 and 2021, respectively. The Company is party to an MSA (“MSA Taiwan”) with UBI Pharma, Inc. (“UBI-P”). Under the MSA Taiwan, UBI-P will provide the Company with manufacturing, quality control, testing, validation, and supply services. Payment terms are mutually agreed in connection with each work order relating to services rendered. No amounts were due to UBI-P as of December 31, 2020 or September 30, 2021, respectively. The Company is party to an MSA (“MSA UBP”) with United BioPharma, Inc. (“UBP”). Under the MSA UBP, UBP will provide the Company with manufacturing, testing and validation. Payment terms are within 45 days of the of invoice receipt. Total amounts due to UBP pursuant to this MSA were each $ 0 million and $ 5.9 million as of December 31, 2020 and September 30, 2021, respectively. Total service fees incurred were each $ 0.0 million and $ 14 million for the nine months ended September 30, 2020 and 2021, respectively. The Company is party to an MSA (“COVID MSA”) with UBI relating to the Company’s COVID-19 program. The COVID MSA provides that UBI acts as COVAXX’s agent with respect to matters relating the Company’s COVID-19 program and provides research, development, manufacturing and back office administrative services to the Company. The Company pays for services based on the UBI costs incurred plus a markup of 10.0 % and reimburses for certain pass-through costs. The Company is party to a four-company MSA with UBI, UBI-Asia and United BioPharma, Inc (“UBP”). The Company is an exclusive licensee of technologies related to diagnostics, vaccines, and therapies for COVID-19 (“COVID-19 Relief MSA”). The MSA established the terms under which UBI-Asia provides research, development, testing and manufacturing services to the Company and UBP provides contract development and manufacturing services to the Company. The four companies party to the COVID-19 Relief MSA share common ownership through UBI. In aggregate, total amounts due to related parties under the COVID MSA and the COVID-19 Relief MSA were $ 2.9 million and $ 10.3 million as of December 31, 2020 and September 30, 2021, respectively. Total service fees incurred under the COVID MSA and the COVID-19 Relief MSA were $ 10.3 million and $ 16.9 million during the nine months ended September 30, 2020 and 2021, respectively, with $ 3.7 million representing a prepaid production deposit at September 30, 2021. In August 2021, as partial consideration for the rights and licenses the company received pursuant to the Platform License Agreement, the company granted UBI a warrant to purchase 1,928,020 shares of our Class A common stock. As of September 30, 2021, all 1,928,020 shares of Class A common stock underlying the UBI Warrant are exercisable, and are not subject to vesting. The UBI Warrant has a term the earlier of five years from the date of issuance or acquisition of the Company. Taiwan Centers for Disease Control Grant (“Taiwan CDC”) UBI-Asia, which is responsible for applying for and managing grants on our behalf under the COVID-19 program, was awarded a grant by the Taiwan CDC for COVID-19 vaccine development. The Company contracted with UBI-Asia to conduct a two- phase study of a COVID-19 vaccine clinical trial in Taiwan. The grant provides that costs incurred to complete the two phases of the clinical trial will be reimbursed based on the achievement of certain milestones as provided in the agreement. During the nine months ended September 30, 2021, the Company has provided for an estimate of $ 7.2 million against Phase II study costs incurred during this time; this was recorded as contra research and development expenses in its condensed consolidated statement of operations. UBI IP Holdings The Company provides administrative services to UBI IP Holding (“UBI-IP”). Under the arrangement, the Company issues vendor payments and provides technical services mostly for legal services on behalf UBI-IP. The Company bills UBI-IP for services based on the costs incurred with no markup. Total amounts due to the Company from UBI-IP were each $ 0.4 million as of December 31, 2020 and September 30, 2021, respectively. Total related party operating activity, including the activity described above, for the three and nine months ended September 30, 2020 and 2021 is as follows (in thousands): For the Three Months For the nine Months Ended September 30, Ended September 30, 2020 2021 2020 2021 Operating expenses Research and development Services provided by related parties $ 7,425 $ 13,515 $ 8,898 $ 38,667 Taiwan CDC grant reimbursement from related party (474) — (474) (7,199) General and administrative 1,858 355 2,343 1,173 Services provided by related parties $ 8,809 $ 13,870 $ 10,767 $ 32,641

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	16. Subsequent Events The Company has evaluated subsequent events through December 17, 2021 and has concluded that no events or transactions have occurred that require disclosure in the accompanying consolidated financial statements, except as follows: Issuance of Options In November 2021, the company issued 1,499,085 stock options to employees with a exercise price of $ 13.00 per share in connection with the IPO. Reverse Stock Split On October 29, 2021, the Company effectuated a reverse stock split of 1-for-1.556 (the “Stock Split”) of the Company’s Class A and Class B common stock pursuant to an amendment to the Company’s Amended and Restated Certificate of Incorporation approved by the Company’s board of directors and stockholders. As a result of the Stock Split, the Company also adjusted the share and per share amounts associated with its options and warrants to purchase shares of its common stock. These condensed combined consolidated financial statements have been retroactively adjusted to reflect the Stock Split for all periods presented. Any fractional shares that would have resulted from the Stock Split have been rounded down to the nearest whole share. Initial Public Offering On November 15, 2021, the Company closed its IPO of 6,000,000 shares of Class A common stock at a public offering price of $ 13.00 per share. On November 18, 2021 the Company held a subsequent closing for the issuance of an additional 537,711 shares of Class A common stock pursuant to a 30-day option granted to the underwriters to purchase up to an additional 900,000 shares of Class A common stock at the IPO price, less underwriting discounts and commissions. The aggregate net proceeds to the Company from the offering, after deducting underwriting discounts and commissions and other offering expenses payable by the Company, was approximately $ 71.1 million. Upon the closing of the IPO, all previously outstanding shares of the Company’s redeemable convertible preferred stock were automatically converted into shares of its Class A common stock.

Summary of Significant Accounting Policies (Policy)	9 Months Ended
Summary of Significant Accounting Policies (Policy)	Sep. 30, 2021
Summary of Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited interim condensed combined consolidated financial statements have been prepared pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial reporting. The condensed consolidated financial statements for the periods presented include the accounts of UNS and COVAXX that were parties to the Contribution and Exchange Agreement. All share and per share amounts, as originally recorded by each entity, have been converted to a number of shares and per share amounts using the conversion ratios determined under the Contribution and Exchange Agreement. These interim condensed combined consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting of normal recurring adjustments and accruals) necessary to fairly present the results of the interim periods. The condensed combined balance sheet at December 31, 2020, has been derived from the audited financial statements at that date. Operating results for the three and nine months ended September 30, 2021 and cash flows for the nine months ended September 30, 2021 are not necessarily indicative of the results that may be expected for the fiscal year ended December 31, 2021 or any other future period. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been omitted in accordance with the rules and regulations for interim reporting of the SEC. These interim condensed financial statements should be read in conjunction with the financial statements and notes thereto included in our report for the year ended December 31, 2020. Significant Accounting Policies The significant accounting policies used in preparation of these condensed financial statements are disclosed in our annual financial statements for the year ended December 31, 2020. There have been no changes to the Company’s significant accounting policies during the three and nine months ended September 30, 2021.
Emerging Growth Company Status	Emerging Growth Company Status The Company is an “emerging growth company” (“EGC”), as defined in the Jumpstart Our Business Startups Act (“JOBS Act”) and is permitted to and plans to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. The Company may take advantage of these exemptions until it is no longer an EGC under Section 107 of the JOBS Act, which provides that an EGC can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to avail itself of the extended transition period and, therefore, while the Company is an EGC it will not be subject to new or revised accounting standards at the same time that they become applicable to other public companies that are not EGCs.
Recently Adopted and Issued Accounting Pronouncements	Recently Adopted Accounting Pronouncements In November 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 , (“ASU 2018-18”). The amendments in this update clarify that certain transactions between collaborative arrangement participants should be accounted for as revenue when the collaborative arrangement participant is a customer in the context of a unit of account and precludes recognizing as revenue consideration received from a collaborative arrangement participant if the participant is not a customer. ASU 2018-18 is effective for the Company’s annual reporting periods after December 15, 2020. The Company adopted ASU 2018-18 at January 1, 2021. The adoption of this pronouncement did not have a material impact on the Company’s combined consolidated financial statements or its results of operations. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The new standard will be effective for the Company beginning January 1, 2021. The Company adopted ASU 2019-12 at January 1, 2021. The adoption of this pronouncement did not have a material impact on the Company’s combined consolidated financial statements or its results of operations. Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU 2016-12, “Leases (Topic 842), and associated ASUs related to Topic 842, which requires organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. The new guidance requires that a lessee recognize assets and liabilities for leases, and recognition, presentation and measure in the financial statements will depend on its classification as a finance or operating lease. In addition, the new guidance requires disclosures to help investors and other financial statement users better understand the amount, timing and uncertainty of cash flows arising from leases. The estimated impact on our existing lease agreements is approximately $ 250,000 . The Company has elected to apply the transition requirements as of January 1, 2022. This approach allows for a cumulative effect adjustment in the period of adoption, and prior periods continue to be reported in accordance with historic accounting under ASC 840 “Leases.” Additionally, as an accounting policy election, the Company has chosen to not apply the standard to any existing short-term leases (term of 12 months or less) as this is optional under U.S. GAAP.

Fair Value Measurements (Tables)	9 Months Ended
Fair Value Measurements (Tables)	Sep. 30, 2021
Fair Value Measurements [Abstract]
Schedule of Financial Instruments Measured at Fair Value on a Recurring Basis	December 31, 2020 Level 1 Level 2 Level 3 Total Liabilities Convertible notes payable $ — $ — $ 24,040 $ 24,040 SAFEs — — 24,335 24,335 Warrant liability — — 400 400 $ — $ — $ 48,775 $ 48,775 September 30, 2021 Level 1 Level 2 Level 3 Total Assets Money market funds $ 84,000 $ — $ — $ 84,000 $ 84,000 $ — $ — $ 84,000
Schedule of Activity in Level 3	September 30, 2021 Beginning balance, December 31, 2020 $ 24,680 Level 3 fair value of the principal amount of convertible notes $ 24,040 Change in fair value 2,667 Conversion to Series A preferred stock (26,707) Ending balance September 30, 2021 $ — SAFE Liability Balance at December 31, 2020 $ 24,335 Change in fair value 8,365 Issuance of SAFEs 2,900 Conversion to Series A preferred stock (35,600) Balance at September 30, 2021 $ — Warrants Liability Balance at December 31, 2020 $ 400 Change in fair value 214 Exchange of warrants for shares of Series A preferred stock (614) Balance at September 30, 2021 $ —

Property, Equipment and Licensed Intellectual Property (Tables)	9 Months Ended
	Sep. 30, 2021
Property, Equipment and Licensed Intellectual Property [Abstract]
Property and Equipment, Net	December 31, September 30, 2020 2021 Airplane $ 11,983 $ 11,983 Laboratory and computer equipment 969 1,019 Furniture and fixtures 84 84 Total property and equipment $ 13,036 $ 13,086 Less accumulated depreciation (878) (1,704) Property and equipment, net $ 12,158 $ 11,382
Schedule of Annual Amortization	September 30, 2021 Licensed intellectual property $ 13,320 Less accumulated amortization (103) Licensed intellectual property, net $ 13,217 Amount 2021 (Q4 2021) $ 167 2022 666 2023 666 2024 668 2025 and thereafter 11,050 $ 13,217

Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
Accrued Expenses and Other Current Liabilities (Tables)	Sep. 30, 2021
Accrued Expenses and Other Current Liabilities [Abstract]
Accrued expenses and other current liabilities	December 31, September 30, 2020 2021 Accrued professional fees and other 228 2,240 Accrued payroll and benefits 53 2,138 Accrued interest 33 31 Accrued external research and development 296 725 $ 610 5,134

Convertible Notes Payable (Tables)	9 Months Ended
Convertible Notes Payable (Tables)	Sep. 30, 2021
Notes Payable [Abstract]
Convertible Notes	Convertible Notes Principal Amount Payable Change in Fair Value Accrued Interest Issuance Conversion to Standard Related Party Standard Related Party Standard Related Party Costs Series A Preferred Balance December 31, 2019 $ 11,170 $ 510 $ 33 $ 26 $ 378 $ 4 $ — $ — $ 12,121 Additions 2,040 10,000 1,661 3,119 203 48 (300) 16,771 Settlements (5,500) — — — — — (5,500) September 30, 2020 $ 7,710 $ 10,510 $ 1,694 $ 3,145 $ 581 $ 52 $ (300) $ — $ 23,392 Convertible Notes Principal Amount Payable Change in Fair Value Accrued Interest Issuance Conversion to Standard Related Party Standard Related Party Standard Related Party Costs Series A Preferred Balance December 31, 2020 $ 7,710 $ 10,510 $ 1,972 $ 3,848 $ 674 $ 183 $ (217) $ — $ 24,680 Additions — 2,000 812 1,855 48 121 — — 4,836 Settlements (2,000) — — — (187) — — — (2,187) Amortization — — — — — — 50 — 50 Conversion of Convertible Notes to Series A preferred stock — — — — — — 167 (27,546) (27,379) September 30, 2021 $ 5,710 12,510 $ 2,784 $ 5,703 $ 535 $ 304 $ — $ (27,546) $ —

Notes Payable (Tables)	9 Months Ended
Notes Payable (Tables)	Sep. 30, 2021
Notes Payable [Abstract]
Carrying Value	September 30, 2021 Principal $ 10,989 Unamortized debt issuance cost (198) Carrying amount 10,791 Less: current portion (425) Note payable, net of current portion and debt issuance cost $ 10,366
Annual Principal Payments	Amount 2021 $ 105 2022 429 2023 444 2024 458 2025 and thereafter 9,553 $ 10,989

Convertible Preferred Stock (Tables)	9 Months Ended
Convertible Preferred Stock (Tables)	Sep. 30, 2021
Convertible preferred stock [Abstract]
Schedule of preferred stock	As of September 30, 2021 Issuance Dates Shares issued and outstanding Common Stock Issuable Upon Conversion Series A preferred stock March 2021 62,223,095 39,989,083 Series B preferred stock March 2021 5,441,863 3,497,337 Series B preferred stock June 2021 9,923,711 6,377,700 77,588,669 49,864,120

- Definition

Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644

+ Details

Common Stock (Tables)	9 Months Ended
Common Stock (Tables)	Sep. 30, 2021
Common Stock [Abstract]
Reserved Shares of Common Stock for Issuance	Series A preferred stock 39,989,083 Series B preferred stock 9,875,037 Options issued and outstanding 20,714,308 Options available for future grants 7,169,027 Warrants issued and outstanding to purchase shares of common 2,056,722 79,804,177

Equity Incentive Plans (Tables)	9 Months Ended
Equity Incentive Plans (Tables)	Sep. 30, 2021
Equity Incentive Plan [Abstract]
Schedule of Stock-Based Compensation Expense for Stock Options	Three Months Ended September 30, Nine months ended September 30, 2020 2021 2020 2021 Research and development $ 83 $ 364 $ 206 $ 738 General and administrative 208 1,100 489 4,864 Total stock-based compensation expense $ 291 $ 1,464 $ 695 $ 5,602
Summary of Restricted Stock Activity	Number of Shares Weighted average grant date fair value per share Unvested at December 31, 2020 15,405 $ 0.32 Vested (15,405) $ 0.32 Unvested at September 30, 2021 - $ -

Net Loss Per Share (Tables)	9 Months Ended
Net Loss Per Share (Tables)	Sep. 30, 2021
Net Loss Per Share [Abstract]
Schedule of Excluded Potential Common Shares from Computation of Diluted Net Loss Per Share	Series A preferred stock 39,989,083 Series B preferred stock 9,875,037 Options to purchase common stock 20,714,308 Warrants issued and outstanding to purchase shares of common stock 2,056,722 72,635,150

Related Party Transactions (Tables)	9 Months Ended
Related Party Transactions (Tables)	Sep. 30, 2021
Related Party Transactions [Abstract]
Schedule of Related Party Operating Activity	For the Three Months For the nine Months Ended September 30, Ended September 30, 2020 2021 2020 2021 Operating expenses Research and development Services provided by related parties $ 7,425 $ 13,515 $ 8,898 $ 38,667 Taiwan CDC grant reimbursement from related party (474) — (474) (7,199) General and administrative 1,858 355 2,343 1,173 Services provided by related parties $ 8,809 $ 13,870 $ 10,767 $ 32,641

Nature of the Business (Narrative) (Details) $ / shares in Units, $ in Millions					1 Months Ended
	Nov. 18, 2021 shares	Nov. 15, 2021 USD ($) $ / shares shares	Oct. 29, 2021	Mar. 02, 2021 shares	Oct. 31, 2014 shares
Nature of Business Disclosures [Line Items]
Issuance of stock, shares				57,702,458	32,505,306
Subsequent Event [Member]
Nature of Business Disclosures [Line Items]
Reverse stock split			0.643
Class A Common Stock [Member]
Nature of Business Disclosures [Line Items]
Issuance of stock, shares				10,999,149
Class A Common Stock [Member] \| Subsequent Event [Member]
Nature of Business Disclosures [Line Items]
Issuance of stock, shares	537,711	6,000,000
Share Price \| $ / shares		$ 13.00
Issuance of stock \| $		$ 71.1
Class A Common Stock [Member] \| Subsequent Event [Member] \| 30-Day Option Granted To Underwriters [Member]
Nature of Business Disclosures [Line Items]
Issuance of stock, shares	900,000

Summary of Significant Accounting Policies (Narrative) (Details)	Sep. 30, 2021 USD ($)
Accounting Standards Update 201602 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated impact of lease agreements	$ 250,000

Fair Value Measurements (Narrative) (Details) - USD ($)	1 Months Ended	9 Months Ended	12 Months Ended
Fair Value Measurements (Narrative) (Details) - USD ($)	Aug. 31, 2021	Sep. 30, 2021	Dec. 31, 2020	Aug. 05, 2021	Sep. 30, 2020
Class Of Warrant Or Right [Line Items]
Transfers between levels		$ 0			$ 0
Fair value of preferred stock issued on conversion date			$ 15,600,000
Warrant outstanding		2,056,722
Intangible asset useful life		20 years
Series A-1 Preferred [Member]
Class Of Warrant Or Right [Line Items]
Number of shares available to purchase from vested warrants			205,970
Warrant, contractual term			10 years
Number of warrants exercised			71,862
Warrants, exercise price			$ 0.003
Series A-1 Preferred [Member] \| Maximum [Member]
Class Of Warrant Or Right [Line Items]
Cash proceeds from warrants exercised			$ 1,000
Warrant outstanding			134,106
Class A Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Number of warrants exercised	1,920,020	1,920,020
Warrants, exercise price				$ 12.45
Warrant outstanding				1,928,020
Fair value of warrants				$ 13,300,000

Fair Value Measurements (Schedule of Financial Instruments Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible notes payable		$ 24,040
Simple agreement for future equity		24,335
Warrant liability		400
Liabilities		48,775
Assets	$ 84,000
Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	84,000
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible notes payable		0
Simple agreement for future equity		0
Warrant liability		0
Liabilities		0
Assets	84,000
Level 1 [Member] \| Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	84,000
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible notes payable		0
Simple agreement for future equity		0
Warrant liability		0
Liabilities		0
Assets	0
Level 2 [Member] \| Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	0
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible notes payable		24,040
Simple agreement for future equity		24,335
Warrant liability		400
Liabilities		$ 48,775
Assets	0
Level 3 [Member] \| Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	$ 0

Fair Value Measurements (Schedule of Activity in Level 3) (Details) - Level 3 [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2021 USD ($)
Convertible Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning balance	$ 24,680
Level 3 fair value of the principal amount of convertible notes	24,040
Change in fair value	2,667
Conversion/exchange	(26,707)
Ending balance	0
Simple Agreement for Future Equity [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning balance	24,335
Change in fair value	8,365
Issuance of SAFEs	2,900
Conversion/exchange	(35,600)
Ending balance	0
Warrant Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning balance	400
Change in fair value	214
Conversion/exchange	(614)
Ending balance	$ 0

Property, Equipment and Licensed Intellectual Property (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Property, Plant and Equipment [Line Items]
Depreciation and amortization expense	$ 400		$ 928	$ 363
Intangible asset useful life			20 years
Licensed Technology [Member]
Property, Plant and Equipment [Line Items]
Intangible asset useful life			20 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Depreciation and amortization expense		$ 100		$ 100

Property, Equipment and Licensed Intellectual Property (Property and Equipment, Net) (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment	$ 13,086	$ 13,036
Less accumulated depreciation	(1,704)	(878)
Property and equipment, net	11,382	12,158
Airplane [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	11,983	11,983
Laboratory And Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	1,019	969
Furniture And Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$ 84	$ 84

Property, Equipment and Licensed Intellectual Property (Schedule of Annual Amortization) (Details) - Licensed Technology [Member] $ in Thousands	Sep. 30, 2021 USD ($)
Finite Lived Intangible Assets [Line Items]
Licensed intellectual property	$ 13,320
Less accumulated amortization	(103)
Lincensed intellectual property, net	$ 13,217

Property, Equipment and Licensed Intellectual Property (Schedule of Annual Amortization 2) (Details) - Licensed Technology [Member] $ in Thousands	Sep. 30, 2021 USD ($)
Finite Lived Intangible Assets [Line Items]
2021 (Q4 2021)	$ 167
2022	666
2023	666
2024	668
2025 and thereafter	11,050
Lincensed intellectual property, net	$ 13,217

Accrued Expenses and Other Current Liabilities (Accrued Expenses and Other Current Liabilities) (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Accrued Expenses and Other Current Liabilities [Abstract]
Accrued professional fees and other	$ 2,240	$ 228
Accrued payroll and benefits	2,138	53
Accrued interest	31	33
Accrued external research and development	725	296
Accrued expense and other current liabilities	$ 5,134	$ 610

Convertible Notes Payable (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Debt Instrument [Line Items]
Change in fair value of convertible notes		$ (2,786)	$ (2,667)	$ (4,781)
Convertible Debt [Member]
Debt Instrument [Line Items]
Interest Expense, Debt	$ 100		$ 200
Convertible Debt [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Debt Instrument Interest Rate Stated Percentage	4.80%		4.80%
Debt Instrument, Term			1 year
Convertible Debt [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Debt Instrument Interest Rate Stated Percentage	6.00%		6.00%
Debt Instrument, Term			3 years

Convertible Notes Payable (Convertible Notes) (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Notes Payable [Abstract]
Principle amount payable, standard, beginning balance	$ 7,710	$ 11,170
Principle amount payable, standard, additions		2,040
Principle amount payable, standard, settlements	(2,000)	(5,500)
Principle amount payable, standard, ending balance	5,710	7,710
Principle amount payable, related party, beginning balance	10,510	510
Principle amount payable, related party, additions	2,000	10,000
Principle amount payable, related party, ending balance	12,510	10,510
Change in fair value, standard, beginning balance	1,972	33
Change in fair value, related party, additions	812	1,661
Change in fair value, standard, ending balance	2,784	1,694
Change in fair value, related party, beginning balance	3,848	26
Change in fair value, related party, additions	1,855	3,119
Change in fair value, related party, ending balance	5,703	3,145
Accrued interest, standard, beginning balance	(674)	(378)
Accrued interest, standard, additions	48	203
Accrued interest, standard, settlements	187
Accrued interest, standard ending balance	(535)	(581)
Accrued interest, related party, beginning balance	183	4
Accrued interest, related party, additions	121	48
Accrued interest, related party, ending balance	304	52
Issuance costs, beginning balance	217	0
Issuance costs, amortization	50	300
Issuance costs, conversion	167
Issuance costs, ending balance	0	300
Conversion to Series A preferred stock	27,546
Beginning balance	24,680	12,121
Additions	4,836	16,771
Settlements	(2,187)	(5,500)
Amortization	50	300
Conversion of convertible notes to Series A preferred stock	(27,379)
Ending balance	$ 0	$ 23,392

Notes Payable (Narrative) (Details) - Notes Payable [Member] - USD ($) $ in Thousands	1 Months Ended			3 Months Ended		9 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2018	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	May 05, 2020	Nov. 30, 2019
Debt Instrument [Line Items]
Proceeds from Notes Payable			$ 2,000
2025 Note [Member]
Debt Instrument [Line Items]
Interest Rate, Term Loan		3.40%
Debt Instrument, Face Amount		$ 11,500
Debt Instrument, Periodic Payment	$ 60
Debt Instrument, Maturity Date		Jun. 09, 2025
Debt Instrument, Final Payment		$ 9,400
Deferred Finance Costs, Net		$ 300
Interest Expense, Debt				$ 100		$ 300
2025 Note [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Interest Expense, Debt					$ 100		$ 100
2018 Related Notes [Member]
Debt Instrument [Line Items]
Interest Rate, Term Loan			5.00%
2019 Executive Note [Member]
Debt Instrument [Line Items]
Interest Rate, Term Loan									5.00%
Debt Instrument, Face Amount									$ 100
PPP [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount								$ 300

Notes Payable (Carrying Value) (Details) - Note, 2025 [Member] - Notes Payable [Member] $ in Thousands	Sep. 30, 2021 USD ($)
Debt Instrument [Line Items]
Principal	$ 10,989
Unamortized debt issuance cost	(198)
Total	10,791
Less: current portion	(425)
Note payable, net of current portion and debt issuance cost	$ 10,366

- Definition

Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References + Details

Notes Payable (Annual Principal Payments) (Details) - Note, 2025 [Member] - Notes Payable [Member] $ in Thousands	Sep. 30, 2021 USD ($)
Debt Instrument [Line Items]
2021	$ 105
2022	429
2023	444
2024	458
2025 and thereafter	9,553
Total	$ 10,989

Convertible Preferred Stock (Narrative) (Details)	Mar. 02, 2021	Sep. 30, 2021 $ / shares shares
Convertible preferred stock [Line Items]
Preferred stock, shares authorized		87,223,095
Preferred stock, par value \| $ / shares		$ 0.0001
Series A Preferred Stock [Member]
Convertible preferred stock [Line Items]
Preferred stock, shares authorized		62,223,095
Series B Preferred Stock [Member]
Convertible preferred stock [Line Items]
Preferred stock, shares authorized		25,000,000
UNS [Member]
Convertible preferred stock [Line Items]
Share exchange rate	0.2191
COVAXX [Member]
Convertible preferred stock [Line Items]
Share exchange rate	3.4233

Convertible Preferred Stock (Schedule of Preferred Stock) (Details)	Sep. 30, 2021 shares
Convertible preferred stock [Line Items]
Preferred stock, shares issued	77,588,669
Preferred stock, share outstanding	77,588,669
Common Stock Issuable Upon Conversion	49,864,120
Series A Preferred Stock [Member]
Convertible preferred stock [Line Items]
Preferred stock, shares issued	62,223,095
Preferred stock, share outstanding	62,223,095
Common Stock Issuable Upon Conversion	39,989,083
Series B Preferred Stock [Member]
Convertible preferred stock [Line Items]
Common Stock Issuable Upon Conversion	9,875,037
Series B Preferred Stock Issued March 2021 [Member]
Convertible preferred stock [Line Items]
Preferred stock, shares issued	5,441,863
Preferred stock, share outstanding	5,441,863
Common Stock Issuable Upon Conversion	3,497,337
Series B Preferred Stock Issued June 2021 [Member]
Convertible preferred stock [Line Items]
Preferred stock, shares issued	9,923,711
Preferred stock, share outstanding	9,923,711
Common Stock Issuable Upon Conversion	6,377,700

Simple Agreement for Future Equity (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended					3 Months Ended	9 Months Ended
	Mar. 02, 2021	Jan. 31, 2021	Dec. 31, 2020	Aug. 31, 2020	Apr. 30, 2020	Oct. 31, 2014	Sep. 30, 2020	Sep. 30, 2021	Mar. 31, 2020
Simple Agreement for Future Equity [Line Items]
Simple agreement for future equity			$ 24,335
Shares issued	57,702,458					32,505,306
Change in fair value of simple agreement for future equity							$ 615	$ 8,365
SAFE Arrangements [Member]
Simple Agreement for Future Equity [Line Items]
Proceeds from issuance of simple agreement for future equity		$ 2,900
SAFE 1 [Member]
Simple Agreement for Future Equity [Line Items]
Simple agreement for future equity									$ 400
Shares issued					463,162
Share Price					$ 0.7773
SAFE 2 [Member]
Simple Agreement for Future Equity [Line Items]
Simple agreement for future equity				$ 14,700
SAFE 3 [Member]
Simple Agreement for Future Equity [Line Items]
Proceeds from issuance of simple agreement for future equity			$ 24,300
Series A-2 Stock [Member]
Simple Agreement for Future Equity [Line Items]
Shares issued				6,307,690
Share Price				$ 2.3241

Common Stock (Narrative) (Details)		1 Months Ended
Common Stock (Narrative) (Details)	Mar. 02, 2021 shares	Sep. 30, 2021 $ / shares shares	Oct. 31, 2014 shares
Class Of Stock [Line Items]
Issuance of stock, shares	57,702,458		32,505,306
Common stock, shares authorized		170,650,960
Common stock, par value \| $ / shares		$ 0.0001
UNS [Member]
Class Of Stock [Line Items]
Share exchange rate	0.2191
COVAXX [Member]
Class Of Stock [Line Items]
Share exchange rate	3.4233
Class A Common Stock [Member]
Class Of Stock [Line Items]
Issuance of stock, shares	10,999,149
Shares converted		2,874,984
Conversion ratio		1
Common stock, shares authorized		146,477,113
Common Class B [Member]
Class Of Stock [Line Items]
Issuance of stock, shares	37,388,014
Common stock, shares authorized		24,173,847

Common Stock (Reserved Share of Common Stock for Issuance) (Details)	Sep. 30, 2021 shares
Class Of Stock [Line Items]
Preferred stock	49,864,120
Warrants issued and outstanding to purchase shares of common stock	2,056,722
Reserved Shares of Common Stock	79,804,177
Options [Member]
Class Of Stock [Line Items]
Options issued and outstanding	20,714,308
Options available for future grants	7,169,027
Series A Preferred Stock [Member]
Class Of Stock [Line Items]
Preferred stock	39,989,083
Series B Preferred Stock [Member]
Class Of Stock [Line Items]
Preferred stock	9,875,037

Equity Incentive Plan (Narrative) (Details - shares	1 Months Ended	9 Months Ended
Equity Incentive Plan (Narrative) (Details - shares	Aug. 31, 2021	Sep. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options cancelled	6,342,456
2021 Stock Option and Grant Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price threshold as a percentage of combined voting power		10.00%
Minimum exercise price for grantees under combined voting power threshold		100.00%
Minimum exercise price for grantees under combined voting power threshold		110.00%
Award expiration term		10 years
Award expiration term for grantees under combined voting power threshold		5 years
2021 Stock Option and Grant Plan [Member] \| Class A Common Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Available for issuance under Plan		21,593,830
Number of shares available for grant		7,169,027
Options outstanding		22,331,544
Options exercisable		11,035,590
2021 Stock Option and Grant Plan [Member] \| Common Class B [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Available for issuance under Plan		6,362,456
Options outstanding		9,899,982

Equity Incentive Plan (Schedule of Stock-Based Compensation Expense for Stock Options) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 291	$ 1,464	$ 695	$ 5,602
Research And Development Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	83	364	206	738
General And Administrative Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 208	$ 1,100	$ 489	$ 4,864

Equity Incentive Plan (Summary of Restricted Stock Activity) (Details)	9 Months Ended
	Sep. 30, 2021 $ / shares shares
Equity Incentive Plan [Abstract]
Unvested, Number of Shares, Begining Balance \| shares	15,405
Vested, Number of Shares \| shares	(15,405)
Unvested, Number of Shares, Ending Balance \| shares	0
Unvested, Weighted average grant date fair value per share, beginning balance \| $ / shares	$ 0.32
Vested, weighted average grant date fair value per share \| $ / shares	0.32
Unvested, Weighted average grant date fair value per share, ending balance \| $ / shares	$ 0

Income Taxes (Narrative) (Details) - USD ($)	3 Months Ended		9 Months Ended
Income Taxes (Narrative) (Details) - USD ($)	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Taxes [Abstract]
Income tax expense	$ 0	$ 0	$ 0	$ 0

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

Net Loss Per Share (Schedule of Excluded Potential Common Shares from Computation of Diluted Net Loss Per Share) (Details)	9 Months Ended
	Sep. 30, 2021 shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded potential common shares from computation of diluted net loss per share	72,635,150
Series A Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded potential common shares from computation of diluted net loss per share	39,989,083
Series B Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded potential common shares from computation of diluted net loss per share	9,875,037
Options To Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded potential common shares from computation of diluted net loss per share	20,714,308
Warrants Issued And Outstanding To Purchase Shares Of Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded potential common shares from computation of diluted net loss per share	2,056,722

Commitments and Contingencies (Narrative) (Details)		1 Months Ended	3 Months Ended		9 Months Ended
Commitments and Contingencies (Narrative) (Details)	Mar. 02, 2021 shares	Oct. 31, 2014 shares	Sep. 30, 2021 USD ($)	Sep. 30, 2020 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2020 USD ($)	Aug. 31, 2021 USD ($) ft²
Commitments And Contingencies [Line Items]
Security deposit			$ 20,000.00		$ 20,000.00
Shares issued \| shares	57,702,458	32,505,306
Lease in square feet \| ft²							5,248
Lease, initial term							1 year
Lease obligation							$ 200,000
Maximum [Member]
Commitments And Contingencies [Line Items]
Rent expense			100,000	$ 100,000	100,000	$ 100,000
Indemnification Agreement [Member]
Commitments And Contingencies [Line Items]
Obligations accrued			0		0
Contract Research Organizations [Member]
Commitments And Contingencies [Line Items]
Remaining prepayments			1,000,000.0		1,000,000.0
Contract Manufacturing Organizations [Member]
Commitments And Contingencies [Line Items]
Remaining prepayments			$ 10,900,000		$ 10,900,000

Related Party Transactions (Narrative) (Details) - USD ($)	1 Months Ended	9 Months Ended
	Aug. 31, 2021	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Class A Common Stock [Member]
Related Party Transaction [Line Items]
Number of warrants exercised	1,920,020	1,920,020
UBI [Member]
Related Party Transaction [Line Items]
Mark up percentage		7.50%
Due to related parties		$ 4,000,000.0		$ 3,600,000
Service fees			$ 400,000
UBI [Member] \| Maximum [Member]
Related Party Transaction [Line Items]
Service fees		100,000
UBI [Member] \| Purchase Arrangement With UBI [Member]
Related Party Transaction [Line Items]
Prepaid expenses		1,000,000.0		2,900,000
UBI Asia [Member]
Related Party Transaction [Line Items]
Due to related parties		1,100,000		1,000,000.0
Service fees		700,000	100,000
UBI Asia [Member] \| COVID MSA And COVID-19 Relief MSA [Member]
Related Party Transaction [Line Items]
Research and development		7,200,000
UBI-P [Member]
Related Party Transaction [Line Items]
Due to related parties		5,900,000		0
Service fees		$ 14,000,000	0.0
UBI-P [Member] \| COVID MSA And COVID-19 Relief MSA [Member]
Related Party Transaction [Line Items]
Mark up percentage		10.00%
Due to related parties		$ 10,300,000		2,900,000
Service fees		16,900,000	$ 10,300,000
Prepaid expenses		3,700,000
UBI-P [Member] \| Manufacturing, Quality Control, Testing, Validation And Supply [Member]
Related Party Transaction [Line Items]
Due to related parties		0		0
UBI IP [Member]
Related Party Transaction [Line Items]
Due to related parties		$ 400,000		$ 400,000

Related Party Transactions (Schedule of Related Party Operating Activity) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Services Provided By Related Parties [Member]
Related Party Transaction [Line Items]
Research and development	$ 13,515	$ 7,425	$ 38,667	$ 8,898
General and administrative	13,870	8,809	32,641	10,767
Taiwan CDC Grant [Member]
Related Party Transaction [Line Items]
Reimbursement from related party	0	(474)	(7,199)	(474)
General and administrative	$ 355	$ 1,858	$ 1,173	$ 2,343

Subsequent Events (Narrative) (Details) $ / shares in Units, $ in Millions					1 Months Ended
	Nov. 18, 2021 shares	Nov. 15, 2021 USD ($) $ / shares shares	Oct. 29, 2021	Mar. 02, 2021 shares	Nov. 30, 2021 $ / shares shares	Oct. 31, 2014 shares
Subsequent Event [Line Items]
Shares issued				57,702,458		32,505,306
Common Class A [Member]
Subsequent Event [Line Items]
Shares issued				10,999,149
Subsequent Event [Member]
Subsequent Event [Line Items]
Options issued					1,499,085
Options issued, exercise price \| $ / shares					$ 13.00
Reverse stock split			0.643
Subsequent Event [Member] \| Common Class A [Member]
Subsequent Event [Line Items]
Issuance of stock \| $		$ 71.1
Shares issued	537,711	6,000,000
Share Price \| $ / shares		$ 13.00
Subsequent Event [Member] \| Common Class A [Member] \| 30-Day Option Granted To Underwriters [Member]
Subsequent Event [Line Items]
Shares issued	900,000